Findings from a pilot open-label trial of N-acetylcysteine for the treatment of pediatric mania and hypomania.

ABSTRACT:

Background

Pediatric bipolar disorder is a highly prevalent and morbid disorder and is considered a prevalent public health concern. Currently approved treatments often pose the risk of serious side effects. Therefore, this study assessed the efficacy and tolerability of N-acetylcysteine (NAC), in children and adolescents with bipolar spectrum disorder.

Methods

We conducted a 12-week open-label trial of NAC for treatment of mania and hypomania in children and adolescents ages 5-17 with bipolar spectrum disorder including participants with full and subthreshold manic symptoms, accepting those with and without mixed states with co-occurring depression, and Young Mania Rating Scale scores ≥ 20 and < 40. Symptoms of mania and depression were assessed using the Young Mania Rating

SUBMITTER: Wozniak J 

PROVIDER: S-EPMC9066881 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature